Relating Activating K-Ras Mutations to Small Molecule Sensitivity in Non- Small-Cell Lung Cancer Flavian D. Brown Carleton College Class of 2009.

Slides:



Advertisements
Similar presentations
 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Gliomas slide presentation is not an independent educational.
Advertisements

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.
Interactions Between Vitamin D and Androgen Receptor Signaling in Prostate Cancer Cells Nancy L. Weigel, Ph.D. Baylor College of Medicine.
Gene 210 Cancer Genomics April 29, Key events in investigating the cancer genome M R Stratton Science 2011;331:
Reported by R5 李霖昆 Supervised by 楊慕華 大夫 Genomics-Driven Oncology: Framework for an Emerging Paradigm Review article Journal of Clinical Oncology 31, 15,
Cancer Genetics Is Cancer a Genetic Disease? Cancer is not a classic genetic disease, instead, Genetic background (set-up) has a definite role in cancer.
Research Presentation Jason M. Leibowitz, MD June 25, 2009 Preceptor: Marcia S. Brose, MD PhD Jason M. Leibowitz, MD June 25, 2009 Preceptor: Marcia S.
MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.
Gene 210 Cancer Genomics May 5, Key events in investigating the cancer genome M R Stratton Science 2011;331:
THE GENETIC OF CANCER Increased mitosisTumor formation Tumor suppression gene Hyperactive growth TranslocationPoint mutationAmplification Normal growth.
CDC42 a low molecular weight GTP-binding protein originally designated G(p) and also called G25K Chromosomal location: 1p36.1 The CDC42 protein binds to.
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.
Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor.
K-RAS ( Kirsten RAS ) Mira Han, Pedro Alves. What is K-RAS? A kind of guanine nucleotide (GTP/GDP) binding protein with intrinsic GTPase activity. Member.
Molecular Biology of Cancer What are the environmental influences that are cancer-causing? What is the difference between an oncogene and a proto-oncogene?
Cystic Fibrosis (CF) - gene location. Cystic Fibrosis (CF): Molecular defect.
Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.
In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.
Differential Response of C-RAF and B-RAF Melanoma Lines to Multiple Chemotherapy Treatments Shawna Dougherty Department of Biological Sciences, York College.
Malignant Melanoma and CDKN2A
Advanced Cancer Topics Journal Review 4/16/2009 AD.
MiR-19b/20a/92a regulates the self- renewal and proliferation of gastric cancer stem cells Journal of Cell Science (IF=5.325) 报告人:黄美玲
FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.
Small molecule-induced pancreatic exocrine transdifferentiation: Assay development Kristin Rose Bridget Wagner, Ph.D. Broad Chemical Biology, Broad Institute.
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
From Signal Transduction to Targeted Therapy (Fall 2010) Pin Ling ( 凌 斌 ), Ph.D. Department of Microbiology & Immunology, NCKU ext 5632
IMI CONFIDENTIAL KLF4 regulates adult lung tumor-initiating cells and represses K-Ras-mediated lung cancer Cell Death and Differentiation (26 June 2015.
Group Number: 2 Britney Porter, Sandra Nguyen, Eduardo Vargas and Samender Singh Randhawa.
Aiming at the Wrong Target? Discussion of Abstracts CRA3507 (Alberts) and 3508 (Goldberg) Louis M. Weiner, MD Lombardi Comprehensive Cancer Center Georgetown.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
ROUND TABLE ON PRECLINICAL THERAPETUICS PANEL: Jon Kurie (M.D. Anderson) Eric Holland (MSKCC) Pier Paolo Pandolfi (MSKCC) Charles Sawyers (UCLA) Kevin.
© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.
Characterization of Small Molecule ETS Transcription Factor Binders Nicole M. Martinez Marius S. Pop and Levi A. Garraway Cancer Biology Program.
Personalized Lung Cancer Treatment: Targeting Stem Cell Pathways David M. Jablons, M.D. Professor and Chief Thoracic Surgery Ada Distinguished Professor.
March 5, Lecture Outline Oncogenes Tumor Suppressor Genes Multiple Hit Hypothesis Oncogene Addiction Hypothesis.
BIOLOGY CONCEPTS & CONNECTIONS Fourth Edition Copyright © 2003 Pearson Education, Inc. publishing as Benjamin Cummings Neil A. Campbell Jane B. Reece Lawrence.
The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.
Dr. Hiba Wazeer Al Zou’bi
YEATS4 Is a Novel Oncogene Amplified in Non– Small Cell Lung Cancer That Regulates the p53 Pathway Speaker:Dai-Wei Hsuan Adviser:Dr. Guor-Mour, Her Data:2015/04/22.
Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,
RAS Initiative at the Federally Funded Research and Development Center at Frederick Presented By: Sara S. Hook October 1, 2015.
YEATS4 Is a Novel Oncogene Amplified in Non– Small Cell Lung Cancer That Regulates the p53 Pathway Speaker:Dai-Wei Hsuan Adviser:Dr. Guor-Mour, Her Data:2015/04/22.
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy by J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy,
EGFR exon 20 insertion mutations
Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.
Samsung Genome Institute Samsung Medical Center
Vignesh Ramachandran SMART Summer Research Program
Cell Cycle Checkpoints The Guardian Mechanisms of
Functional role of Pak1/Erk signaling in Rac-related diseases Daniela Araiza-Olivera, Jennifer Rhodes, and Jonathan Chernoff FOX CHASE CANCER CENTER, 333.
Can Drug Discovery Research be Done At An Undergraduate Institution?
Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?  Tony Sourisseau, PhD, Khaled.
Oncogene addiction and synthetic lethality: keys to discovery of new anticancer drugs. Panel A. Normal cells receive environmental signals that activate.
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.
Molecular Basis Of Cancer
Carlos L. Arteaga, Jeffrey A. Engelman  Cancer Cell 
Targeted Therapies in Melanoma: Translational Research at Its Finest
Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung.
Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?  Tony Sourisseau, PhD, Khaled.
Nat. Rev. Urol. doi: /nrurol
Personalized Medicine: Patient-Predictive Panel Power
A novel class I histone deacetylase inhibitor, I-7ab,
Daniel Haber MD PhD Massachusetts General Hospital Cancer Center
A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.
EGFR and cetuximab sensitivity of SCCUAT
Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases. Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases.
Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Non–Small- Cell Lung Cancer  Cheng-Yi Wang, MD, Ting-Ting Chao, PhD, Wei-Tien.
Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.
Synthetic lethality of ROS1 inhibition in E-cadherin–deficient breast tumor cell lines. Synthetic lethality of ROS1 inhibition in E-cadherin–deficient.
Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.
Presentation transcript:

Relating Activating K-Ras Mutations to Small Molecule Sensitivity in Non- Small-Cell Lung Cancer Flavian D. Brown Carleton College Class of 2009

Lung Cancer  Leading cause of death from cancer in the world  Over 90% of NSCLC contain mutations in EGFR, BRAF and K-Ras  Discovery of Gefitnib

Ras Signaling Schubbert et al. (2007) Hyperactive Ras in developmental disorders and cancer. Nature Review of Cancer, Vol Oncogenic Mutation ← ← ←

Hypothesis  NSCLC tumors are genetically sensitized due to changes in cellular state secondary to activating K- Ras mutations. - Different drug targets - Oncogene Addiction

Small Molecule Screens + DMSO Control 100nl Pin Transfer Hrs 72Hrs 2-10Hrs cell adherence 24 Hrs

A549: Hits Highlighted Color coding on the images: Red = unbiased commercial compound Forma set Green = bioactives (including kinase inhibiting drugs) Magenta = HDAC biased DOS Blue = commercial kinase biased (CBkinase) Yellow = analyticon purified natural products Black = DMSO control plate Gray = +con dose plate Hits From Primary Screen

Assay Development

Small Molecule Sensitivity

Structural Activity Relationship Aromatic group at the opposite end of structures Carbon spacer can be rigid or flexible Hydroxamic acids attached to a 4 or 5 carbon chain

Future Investigations  Analyze signaling downstream of the activating mutation -Immunofluorescence -Western Blotting  Target Identification - Pull down assay  Correlate phenotypic data with genetic data - SNP copy number

Impact  Genotype specific inhibitors for K-Ras mutants  Paradigm for investigating genotype- phenotype relationships in other malignancies - WGAS for somatic alterations  Molecularly targeted cancer therapeutics.

Acknowledgements Principle Investigator - Stuart L.Schreiber, Ph.D Mentor - Gopal S. Ramachandran, Ph.D Summer Research Program in Genomics - Shawna Young - Lucia Vielma - Maura L. Silverstein - Bruce Birren, Ph.D Collaborators - Jordi Barretina, Ph.D - Damian W. Young, Ph.D Broad Institute Screening - Nicola Tolliday, Ph.D - Josh Bittker, Ph.D - Melanie de Silva - Kate Hartland

References 1. Arcaro, A. The small GTP-binding protein Rac promotes the dissociation of gelsolin from actin filaments in neutrophils. J. Biol.Chem. 273, 805–813 (1998) 2. Bourne, H. R., Sanders, D. A. & McCormick, F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature 348, 125–132 (1990). 3. Diaz et al. Complex effects of Ras proto-oncogenes in tumorigenesis. Carcinogenesis, Vol. 25, No. 4, (2004). 4. Downward, J. Targeting RAS signaling pathways in cancer therapy. Nature Rev. Cancer 3, 11–22 (2003). 5. Gibbs, J. B. & Oliff, A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 143–166 (1997). 6. Herrmann, C. Ras–effector interactions: after one decade. Curr. Opin. Struct. Biol. 13, 122–129 (2003) 7. Lynch et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine. Vol. 350 No.21, (2004) 8. Paez, et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science. 304, 1497 (2004). 9. Repasky, G. A., Chenette, E. J. & Der, C. J. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 14, 639–647 (2004). 10. Schubbert et al. Hyperactive Ras in developmental disorders and cancer. Nature, Vol (2007) 11. Swanson et al.; Raymond, J. Hohl. Anti-Cancer Therapy: Targeting the Mevalonate. Current Cancer Drug Target 2006, 6, Vetter, I. R. & Wittinghofer, A. The guanine nucleotidebinding switch in three dimensions. Science 294, 1299–1304 (2001). 13. Zhang et al. Knockdown of Mutant K-ras Expression by Adenovirus-Mediated siRNA Inhibits the In Vitro and in Vivo Growth of Lung Cancer Cells. Cancer Biology and Therapy (2006) 14. Zhang et al. Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small lung cancer. Genetic Vaccines and Therapy 3:5 (2005)